Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2023 | Challenges with cenobamate use in focal epilepsy

Christian Brandt, MD, Bielefeld University, Bielefeld, Germany, discusses cenobamate, a recent addition to epilepsy treatment options for focal drug-refractory epilepsy. Despite its pharmacokinetic interactions and specific regulations for up-titration, cenobamate has demonstrated strong efficacy, with seizure-free rates as high as 20% during pivotal trials. However, there is still a need to develop new medications for those who do not achieve good results using current treatments, with ongoing clinical trials offering hope. This interview took place at the European Academy of Neurology (EAN) 2023 Congress in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Christian Brandt reports the following disclosures: Honoraria for speaking or consulting activities from Angelini, Eisai, Equilibre, GW Pharmaceuticals, Jazz Pharmaceuticals, Johnson&Johnson, Marinus, UCB Pharma, Xenon and Zogenix.